Strepsils med Honning og Citron Munnsogstafla Iceland - Icelandic - LYFJASTOFNUN (Icelandic Medicines Agency)

strepsils med honning og citron munnsogstafla

reckitt benckiser healthcare (scandinavia) a/s - dichlorobenzylalcohol; amylmetacresolum inn - munnsogstafla

Strepsils Cool (Strepsils med Menthol og Eucalyptus) Munnsogstafla Iceland - Icelandic - LYFJASTOFNUN (Icelandic Medicines Agency)

strepsils cool (strepsils med menthol og eucalyptus) munnsogstafla

reckitt benckiser healthcare (scandinavia) a/s - amylmetacresolum inn; dichlorobenzylalcohol - munnsogstafla

Strefen Orange Sukkerfri (Steflam) Munnsogstafla 8,75 mg Iceland - Icelandic - LYFJASTOFNUN (Icelandic Medicines Agency)

strefen orange sukkerfri (steflam) munnsogstafla 8,75 mg

reckitt benckiser healthcare (scandinavia) a/s - flurbiprofenum inn - munnsogstafla - 8,75 mg

Strefen Munnsogstafla 8,75 mg Iceland - Icelandic - LYFJASTOFNUN (Icelandic Medicines Agency)

strefen munnsogstafla 8,75 mg

reckitt benckiser healthcare (scandinavia) a/s - flurbiprofenum inn - munnsogstafla - 8,75 mg

Strepsils Ingefær (Strepsils Warm) Munnsogstafla Iceland - Icelandic - LYFJASTOFNUN (Icelandic Medicines Agency)

strepsils ingefær (strepsils warm) munnsogstafla

reckitt benckiser healthcare (scandinavia) a/s - amylmetacresolum inn; dichlorobenzylalcohol - munnsogstafla

Sylvant European Union - Icelandic - EMA (European Medicines Agency)

sylvant

recordati netherlands b.v. - siltuximab - stór eitilfrumukrabbamein - Ónæmisbælandi lyf - sylvant er ætlað fyrir meðferð fullorðinn sjúklinga með multicentric castleman er sjúkdómur (mcd sem ert hiv veira (hiv) neikvæð og mönnum herpesveiru-8 (hhv-8) neikvæð.

Uplizna European Union - Icelandic - EMA (European Medicines Agency)

uplizna

horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - Ónæmisbælandi lyf - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.